Explore every episode of the podcast Bench to Boardroom

In this episode of Bench to Boardroom, we examine why maximizing value across a life sciences portfolio increasingly requires an asset-specific, geography-agnostic approach rather than relying on the traditional “U.S. first, Europe second, rest of world later” launch model. Through examples in oncology/hematology, cell and gene therapy, and immunology, the discussion explores how launch sequencing, emerging regulatory pathways, evidence generation, market access strategy, and international pricing dynamics can materially influence net present value (NPV), time to patient access, and long-term commercial success. The episode argues that the most valuable portfolios of the future will be built not by following convention, but by strategically matching each asset with the launch sequence that optimizes both enterprise value and patient impact.

In this episode of Bench to Boardroom, we explore why not all technology investments in life sciences are created equal — and why following the hype around AI and digital transformation may generate far weaker returns than many executives expect. The discussion examines where emerging technologies can create meaningful strategic advantage across clinical development, commercialization, market access, launch sequencing, regulatory intelligence, manufacturing, and supply chain operations, while also highlighting where excessive or poorly targeted tech investment may lead to diminishing returns. Ultimately, the episode argues that the leaders who win with technology are not those investing the most, but those investing most intelligently — aligning technology with the realities of science, operations, and commercial execution.

Launching innovative medicines can no longer follow conventional precedent. The old formula -- U.S. first, Europe second, rest of world later -- is increasingly misaligned with the realities of today’s health policy, pricing, and market access environment.

And for some assets, following the traditional launch sequence may actually destroy long-term value.

Not because the science is flawed.

But because the strategy is.

The term Portfolio Strategy gets used constantly in life sciences. Board decks use it. Investors use it. Management teams use it. Consultants use it. But too often, portfolio strategy is treated as a static spreadsheet exercise -- ranking assets, cutting budgets, and reallocating headcount. In this episode, we discuss why (and how) real portfolio strategy is far more consequential than that.

Short trailer introducing the Bench to Boardroom podcast